Loading

AAVogen

June 04, 2024
Company Presentation
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 4
AAVogen is a preclinical stage biotech company that develops gene therapeutics for inclusion body myositis, heart failure and other muscle wasting disease states. This includes proprietary liver de-targeted/muscle specific AAV capsids (AVGN6.1, 6.2, 6.3 & 6.4) and AVGN7; a patented gene therapeutic that prevents wasting of skeletal and cardiac muscle. Licensing opportunities are sought for the capsids while AVGN7 is being developed to treat sporadic inclusion body myositis, heart failure and rare muscle/neuromuscular diseases.
AAVogen
Company Website: https://aavogen.com/
Lead Product in Development: AVGN7
Number Of Unlicensed Products (For Which You Are Seeking Partners): 5

Company HQ City

Rockville

Company HQ State

MD

Company HQ Country

United States

CEO/Top Company Official

Buel D. Rodgers, PhD

Development Phase of Primary Product

Pre-Clinical
Speakers
Buel Rodgers, PhD
CEO
AAVogen
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS